Learn more about the human SLC transporter substrate identification assay including:
- Background information
- Assay details and protocol summary
- Data generated in the SLC transporter substrate identification assay
Learn more about the human SLC transporter substrate identification assay including:
Tags: Fact Sheets, ADME/DMPK
Learn more about our PBMC proliferation assay including:
Tags: Fact Sheets, Toxicology & Safety
Learn more about the P-gp substrate identification assay including:
Tags: Fact Sheets, ADME/DMPK
Drug-drug interaction (DDI) studies are an important part of the regulatory drug development process. The US FDA, EMA and Japanese PMDA have issued guidance on the conduct of these DDI studies, however, a harmonised guidance is currently under review (ICH M12) and is expected to be adopted in April 2024. The risk of DDI can be assessed in vitro and data analysed using models of varying complexity. As identifying potential safety issues is the main purpose of these studies, many of the models have been developed to over-estimate the risk of DDI .This, however, needs to be balanced with the risk of false positives and the potential of unnecessary clinical DDI studies which are expensive and time consuming to perform. It is essential, therefore, to choose the most accurate model when analysing data from in vitro DDI studies.
In this poster, we focus on:
Read our poster to learn more about our research!
LC-MS/MS produces highly sensitive, specific and reproducible data, however, throughput can be a limitation and this can lead to a bottleneck in sample analysis from pharmacokinetic (PK) studies.
In this poster, we focus on:
Read our poster to learn more about our research!
The Echo® MS system, developed by Sciex, uses Acoustic Ejection Mass Spectrometry (AEMS). This chromatography-free technology generates sample droplets and introduces small reproducible volumes of 2.5nL (scalable to 25nL with multiple injections) to the mass spectrometer via an Open Port Interface with minimal carryover. It not only reduces sample requirements, it also facilitates dramatic increases in throughput with the potential to run 1 second cycle times. Despite these advantages, current potential limitations include reduced sensitivity compared to conventional LC-MS/MS and interference due to lack of separation.
In this poster, we focus on:
Read our poster to learn more about our research!
Date: 23 January 2023
Venue: County Hall, London, UK
Attendees: Florence Eustache, David Pardoe
Evotec is an Industry Sponsor at BioSeed 2023, the early-stage life sciences investment event, organised by OBN.
Our Senior Vice President, Head of Global Molecular Architects, David Pardoe and Vice President Business Development, Florence Eustache will make a keynote presentation on:
The AI paradigm shift: Just a flash in the pan or here to stay?
If you wish to meet with us in London, get in touch via the form below, we will be happy to arrange a meeting.
Date: 15 - 19 January 2023
Location: Keystone Resort, CO
Jeremie Boucher, Evotec's SVP, Head of Metabolic Disease, will present at the Keystone Symposia on 'Adipose Tissue: Energizing Good Fat' in Colorado, United States. Jeremie's discussion “Adipose Tissue Targets in Metabolic Disease” will cover several different potential therapeutic targets or pathways in adipose tissue, to treat #metabolicdiseases
Tags: Events
Date: 9 - 12 January 2023
Location: San Francisco, CA
Our experts, Jon Gunther and Nathalie Joly, will be available on site to discuss your drug discovery and R&D requirements. Get in touch via the Biotech Showcase partneringONE app or via email - info@evotec.com
Tags: Events
The discovery of (1R, 3R)-1-(3-chloro-5-fluorophenyl)-3-(hydroxymethyl)-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile, a potent and selective agonist of human transient receptor potential cation channel subfamily m member 5 (TRPM5) and evaluation of as a potential gastrointestinal prokinetic agent
This publication details the discovery of a series of selective agonists for Transient Receptor Potential Melastatin 5 (TRPM5) culminating with the identification of a lead compound.
Gastrointestinal (GI) disease including inflammatory bowel disease (ulcerative colitis and Crohn’s disease), and GI motility disorders (neuropathic constipation (NC), and gastroparesis) are serious life limiting conditions for patients. TRPM5 is a non-selective monovalent cation channel activated by intracellular Ca2+ increase which, within the GI system, plays a critical role of propagating the signal through membrane depolarization and initiating the release of Interleukin (IL)-25 and other paracrine factors. We hypothesized that a TRPM5 agonist will activate the release of IL-25 and non-neuronal ACh, leading to improvement in motility through a prokinetic mechanism.
In the paper we describe:
Tags: Articles & Whitepapers, In vitro Biology, Metabolic Disease & Complications